144 related articles for article (PubMed ID: 32399162)
1. Comparison of bortezomibcyclophosphamide- dexamethasone versus bortezomib-dexamethasone based regimens in newly diagnosed multiple myeloma patients.
Ciftciler R; Goker H; Buyukasik Y; Sayınalp N; Haznedaroglu IC; Aksu S; Ozcebe O; Demiroglu H
Hematol Rep; 2020 May; 12(1):8267. PubMed ID: 32399162
[TBL] [Abstract][Full Text] [Related]
2. Bortezomib-based Triplet Regimens for Remission Induction in Multiple Myeloma.
Toor SH; Satti TM; Iftikhar R; Mahmood SK; Shamshad GU; Rehman JU
J Coll Physicians Surg Pak; 2020 May; 30(5):527-531. PubMed ID: 32580853
[TBL] [Abstract][Full Text] [Related]
3. Real-World Outcomes in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma Treated With Bortezomib/Cyclophosphamide/Dexamethasone and Bortezomib/Lenalidomide/Dexamethasone as Upfront Treatment.
Saeed N; Khan Z; Jehanzeb H; Shaikh T; Shaikh U; Adil SN; Madni V; Fatima H; Abiha UE; Ali N
Cureus; 2024 Apr; 16(4):e58999. PubMed ID: 38800157
[TBL] [Abstract][Full Text] [Related]
4. Adding Cyclophosphamide to Bortezomib and Dexamethasone was not Associated With Improved Outcomes of Patients With Newly Diagnosed Light Chain Amyloidosis: A Retrospective Study.
Zhang Y; Duncanson L; Brayer J; Reu F; Hansen D; Alsina M; Nishihori T; Ochoa-Bayona J; Liu H; Shain K; Thompson Z; Baz R; Blue B
Clin Lymphoma Myeloma Leuk; 2022 Aug; 22(8):e770-e776. PubMed ID: 35504808
[TBL] [Abstract][Full Text] [Related]
5. Bortezomib and low-dose dexamethasone with or without continuous low-dose oral cyclophosphamide for primary refractory or relapsed multiple myeloma: a randomized phase III study.
Kropff M; Vogel M; Bisping G; Schlag R; Weide R; Knauf W; Fiechtner H; Kojouharoff G; Kremers S; Berdel WE
Ann Hematol; 2017 Nov; 96(11):1857-1866. PubMed ID: 28905189
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of dose-attenuated bortezomib, cyclophosphamide and dexamethasone ("VCD-Lite") in very old or otherwise toxicity-vulnerable adults with newly diagnosed multiple myeloma.
Tuchman SA; Moore JO; DeCastro CD; Li Z; Sellars E; Kang Y; Long G; Gasparetto CG
J Geriatr Oncol; 2017 May; 8(3):165-169. PubMed ID: 28256432
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of bortezomib, cyclophosphamide and dexamethasone as induction therapy in multiple myeloma: DSMM XI trial.
Einsele H; Engelhardt M; Tapprich C; Müller J; Liebisch P; Langer C; Kropff M; Mügge LO; Jung W; Wolf HH; Metzner B; Hart C; Gramatzki M; Hertenstein B; Pfreundschuh M; Rösler W; Fischer T; Maschmeyer G; Kanz L; Hess G; Jäger E; Bentz M; Dürk HA; Salwender H; Hebart H; Straka C; Knop S
Br J Haematol; 2017 Nov; 179(4):586-597. PubMed ID: 28961309
[TBL] [Abstract][Full Text] [Related]
8. Bortezomib, epirubicin, and dexamethasone (PAD) results in superior free-progression survival compared to bortezomib, cyclophosphamide, and dexamethasone (VCD) treatment in non-transplantation newly diagnosed multiple myeloma patients aged between 50 to 65: a retrospective single-center analysis in non-transplant patients.
Chen L; Yi K; Lan H; Zhang Y; Jin S; Mou X; Xian H; Fu W; Li R
Ann Transl Med; 2022 Jun; 10(12):674. PubMed ID: 35845500
[TBL] [Abstract][Full Text] [Related]
9. Bortezomib-cyclophosphamide-dexamethasone (VCD) versus bortezomib-thalidomide-dexamethasone (VTD) -based regimens as induction therapies in newly diagnosed transplant eligible patients with multiple myeloma: a meta-analysis.
Leiba M; Kedmi M; Duek A; Freidman T; Weiss M; Leiba R; Nagler A; Avigdor A
Br J Haematol; 2014 Sep; 166(5):702-10. PubMed ID: 24861981
[TBL] [Abstract][Full Text] [Related]
10. Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma.
Mai EK; Bertsch U; Dürig J; Kunz C; Haenel M; Blau IW; Munder M; Jauch A; Schurich B; Hielscher T; Merz M; Huegle-Doerr B; Seckinger A; Hose D; Hillengass J; Raab MS; Neben K; Lindemann HW; Zeis M; Gerecke C; Schmidt-Wolf IG; Weisel K; Scheid C; Salwender H; Goldschmidt H
Leukemia; 2015 Aug; 29(8):1721-9. PubMed ID: 25787915
[TBL] [Abstract][Full Text] [Related]
11. Treatment Patterns and Clinical and Economic Outcomes in Patients With Newly Diagnosed Multiple Myeloma Treated With Lenalidomide- and/or Bortezomib-containing Regimens Without Stem Cell Transplant in a Real-world Setting.
Chari A; Parikh K; Ni Q; Abouzaid S
Clin Lymphoma Myeloma Leuk; 2019 Oct; 19(10):645-655. PubMed ID: 31377207
[TBL] [Abstract][Full Text] [Related]
12. Upfront bortezomib, lenalidomide, and dexamethasone compared to bortezomib, cyclophosphamide, and dexamethasone in multiple myeloma.
Uttervall K; Borg Bruchfeld J; Gran C; Wålinder G; Månsson R; Lund J; Gahrton G; Alici E; Nahi H
Eur J Haematol; 2019 Sep; 103(3):247-254. PubMed ID: 31231833
[TBL] [Abstract][Full Text] [Related]
13. Network Meta-Analysis of Once Weekly Selinexor-Bortezomib-Dexamethasone in Previously Treated Multiple Myeloma.
Dolph M; Tremblay G; Gilligan AM; Leong H
J Health Econ Outcomes Res; 2021; 8(2):26-35. PubMed ID: 34616855
[No Abstract] [Full Text] [Related]
14. Bortezomib-based strategy with autologous stem cell transplantation for newly diagnosed multiple myeloma: a phase II study by the Japan Study Group for Cell Therapy and Transplantation (JSCT-MM12).
Sunami K; Matsumoto M; Fuchida SI; Omoto E; Takamatsu H; Adachi Y; Choi I; Fujishima N; Kiguchi T; Miyamoto T; Maeda A; Suzumiya J; Yamamura R; Nagafuji K; Nakazato T; Kuroda Y; Yujiri T; Takamatsu Y; Harada M; Akashi K
Int J Clin Oncol; 2019 Aug; 24(8):966-975. PubMed ID: 30937622
[TBL] [Abstract][Full Text] [Related]
15. Comparison of cyclophosphamide-thalidomide-dexamethasone to bortezomib-cyclophosphamide-dexamethasone as induction therapy for multiple myeloma patients in Brazil.
Vigolo S; Zuckermann J; Bittencourt RI; Silla L; Pilger DA
Hematol Oncol Stem Cell Ther; 2017 Sep; 10(3):135-142. PubMed ID: 28636891
[TBL] [Abstract][Full Text] [Related]
16. [A cohort study comparing the efficacy and safety of bortezomib plus dexamethasone versus bortezomib, epirubicin and dexamethasone in patients with multiple myeloma].
Hao QY; Chen H; Liu KY; Wen L; Huang XJ; Lu J
Zhonghua Nei Ke Za Zhi; 2016 Sep; 55(9):689-94. PubMed ID: 27586976
[TBL] [Abstract][Full Text] [Related]
17. The impact of induction regimen on transplant outcome in newly diagnosed multiple myeloma in the era of novel agents.
Chakraborty R; Muchtar E; Kumar S; Buadi FK; Dingli D; Dispenzieri A; Hayman SR; Hogan WJ; Kapoor P; Lacy MQ; Leung N; Gertz MA
Bone Marrow Transplant; 2017 Jan; 52(1):34-40. PubMed ID: 27548464
[TBL] [Abstract][Full Text] [Related]
18. Carfilzomib-Dexamethasone Versus Bortezomib-Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Overall Survival, Safety, and Subgroups.
Orlowski RZ; Moreau P; Niesvizky R; Ludwig H; Oriol A; Chng WJ; Goldschmidt H; Yang Z; Kimball AS; Dimopoulos M
Clin Lymphoma Myeloma Leuk; 2019 Aug; 19(8):522-530.e1. PubMed ID: 31160237
[TBL] [Abstract][Full Text] [Related]
19. [Bortezomib-based induction therapy followed by autologous hematopoietic stem cell transplantation in multiple myeloma].
Huang B; Li J; Liu J; Gu J; Zheng D; Xu D; Zou W; Wang H
Zhonghua Nei Ke Za Zhi; 2014 Nov; 53(11):865-72. PubMed ID: 25586356
[TBL] [Abstract][Full Text] [Related]
20. Carfilzomib-dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: secondary analysis of the phase 3 ENDEAVOR study.
Goldschmidt H; Moreau P; Ludwig H; Niesvizky R; Chng WJ; Joshua D; Weisel K; Spencer A; Orlowski RZ; Feng S; Iskander KS; Dimopoulos MA
Leuk Lymphoma; 2018 Jun; 59(6):1364-1374. PubMed ID: 28937327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]